Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC) (Q64623104)
Jump to navigation
Jump to search
clinical trial
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC) |
clinical trial |
Statements
A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Combination With Sorafenib as First Line Treatment in Patients With RAS Mutant Hepatocellular Carcinoma (HCC) (English)
0 references
27 September 2013
0 references
29 July 2015
0 references
14
0 references
18 year
0 references